Navigation Links
Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
Date:4/20/2012

SAN FRANCISCO, April 20, 2012 /PRNewswire/ -- Health insurers should use both medical and pharmacy data to forecast specialty medication utilization and improve outcomes for members, according to a new study by pharmacy benefit manager Prime Therapeutics (Prime). The study will be presented today at the Academy of Managed Care Pharmacy (AMCP)'s 24th Annual Meeting & Expo in San Francisco.

Pharmacy benefit managers (PBMs) have experienced a rapid rise in expensive specialty prescription drug use within the past few years. In 2011, specialty drugs comprised 0.5 percent of all claims but 15.2 percent of all prescription benefit expenditures across Prime's member network. In addition, the average specialty per-prescription cost was $2,637 in 2010 and total paid per capita increased 12.9 percent from 2010 ($10.24 to $11.36 per member per month). Previous studies have estimated that specialty medication drug spend could increase from 20 percent to 50 percent by 2030, highlighting the need for health insurers to better understand how to trend and forecast these costs due to rapid growth rate.

"Specialty drugs offer life-saving treatment for patients with chronic illnesses, but they also carry a huge price tag, continuing to rise by double digits each year," said Patrick Gleason, PharmD, director of clinical outcomes assessment at Prime. "Health insurers and plan sponsors need to be able to forecast these costs and also ensure the best outcomes for their members. For example, it's critical that insurers understand that of the 81.9 percent of members with Hepatitis C identified as untreated many are likely to receive care in the near future because new drugs have recently become available."

According to Prime's analysis, it may be easy to identify prevalence and treatment rates via International Classification of Disease, Ninth Revision (ICD9), procedure code and pharmacy claims for some diseases. However, more sophisticated algorithms may be nee
'/>"/>

SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... -- The potential of the pulmonary route ... agents has been receiving undeniable attention with the recent ... The crucial formulation considerations for orally inhaled products together ... role in the efficiency of pulmonary delivery, and great ... formulation techniques and devices in recent years. ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 /PRNewswire/ ... destacado desarrollador y fabricante de herramientas de precisión ... y tratamiento de la enfermedad vascular periférica y ... ADVISE ( Ad enosine V asodilator ... II durante la sesión de ensayo clínico hot ...
(Date:5/23/2013)... EDGE, N.J. , May 23, 2013 ... a commercial stage medical device company that develops and ... successful completion of its rights offering.  In addition, the ... March 2011 warrants expired on May 17, 2013. ... of $3.0 million from the rights offering.   A portion ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
(Date:5/24/2013)... commonly used to treat glaucoma may cause droopy eyelids ... according to a new study. The drugs, known ... eye pressure, have already been shown to cause blurred ... said, suggesting that the new findings could lead to ... conservative when prescribing these drugs, the researchers added, particularly ...
(Date:5/24/2013)... of highly respected Alzheimer,s researchers failed to replicate what ... this brain disease when they were published last year ... presented online Feb. 9, 2012, suggested that the drug ... of beta amyloid plaques (Aβ) a pathological hallmark ... According to the authors of the 2012 report, drug ...
(Date:5/24/2013)... New York, New York (PRWEB) May 24, 2013 ... da Vinci lawsuit involving Intuitive Surgical Inc.’s da ... According to court records, a Washington State Court ... not committed negligence in training a surgeon who performed ... several years later. The patient’s family had alleged ...
(Date:5/24/2013)... 2013 Dwell Media LLC ... as Executive Vice President of Digital for Dwell Media. ... represented a large portion of Yahoo's global media business. ... develops a fully-integrated commerce unit to launch in 2014. ... digital content for leading firms in Silicon Valley. Dwell, ...
(Date:5/24/2013)... 24 (HealthDay News) -- People with high levels of ... die of liver disease than those with lower levels, ... cadmium in urine is evidence of long-term exposure to ... and tobacco smoke, the Johns Hopkins researchers explained. ... cadmium directly causes liver disease but instead suggest an ...
Breaking Medicine News(10 mins):Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Yahoo Commerce Head Joins Leadership at Dwell Media 2Health News:High Cadmium Levels May Raise Risk for Dying From Liver Disease: Study 2
... but often deadly disease that can strike at any time ... and in the past was referred to as a silent ... ovarian cancer that can assist in early detection. Experts at ... of preventive methods, understand the risks and recognize potential warning ...
... that the hormone estrogen may help reverse advanced pulmonary hypertension, ... million individuals in the U.S., mostly women, and can lead ... progressive increase in blood pressure in the main pulmonary artery, ... to the lungs. The rise in pressure impairs heart function ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, ... increasing rates of drug-resistant tuberculosis, health officials say the disease ... least so far. But, they add, the ease of ... one should think they,re beyond risk. "Drug-resistant TB exists ...
... The demand for transparency through publicly available healthcare data ... and clinical data for research, and for clinical trials data ... a measurable impact on research and policy making. A new ... in Electronic Health Information at the University of Ottawa and ...
... spent glued to their PlayStation 3, Xbox 360 or Nintendo ... perhaps? Improved concentration? Superior driving skills? Over the past ... action video games such as Medal of Honor or Unreal ... in a paper published this week in the journal Frontiers ...
... HealthDay Reporter , WEDNESDAY, Sept. 14 (HealthDay News) ... jumped dramatically worldwide, from about 640,000 in 1980 to more ... Over the same period, the number of cases of ... from that cancer have declined, although in 2010 it still ...
Cached Medicine News:Health News:Early detection is key in the fight against ovarian cancer 2Health News:Early detection is key in the fight against ovarian cancer 3Health News:Estrogen treatment may help reverse severe pulmonary hypertension 2Health News:Estrogen treatment may help reverse severe pulmonary hypertension 3Health News:Officials Tackle Multidrug-Resistant TB in Europe 2Health News:Officials Tackle Multidrug-Resistant TB in Europe 3Health News:New report on creating clinical public use microdata files 2Health News:Put down that Xbox remote: FSU researcher suggests video games may not boost cognition 2Health News:Put down that Xbox remote: FSU researcher suggests video games may not boost cognition 3Health News:Breast Cancer Rates Jump Worldwide, Study Finds 2Health News:Breast Cancer Rates Jump Worldwide, Study Finds 3
... Based on Volks revolutionary MiniQuad, the DynaView ... field view of the retina extending to ... and adult patients. Featuring a minified housing ... DynaView 156 revolutionizes retinopathy of prematurity surgery ...
... MiniQuad XL is recommended for ... entire fundus and in the ... is the ideal lens for ... the operating microscope. It provides ...
... Iridectomy Lens enhances iridectomy procedures by ... (than conventional iridectomy lens designs) with ... on this lens has been increased ... 11.7mm. The MagPlus comes standard with ...
... is an advanced fundus laser lens design ... superior high magnification viewing and treatment of ... computer designed aspheric optics provide improved performance ... Fundus Lens comes standard with LaserWindow® for ...
Medicine Products: